Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence

Background Most countries in the world have launched human papillomavirus (HPV) vaccination programs, and declining HPV prevalences are reported. We aimed to disentangle the influences of calendar time, birth cohort, and age by analyzing HPV prevalences in the population-based cervical screening program using age-period-cohort modeling.Methods All 813 882 primary HPV-based cervical screening tests from women aged 23-64 years between 2014 and 2023 in the capital region of Sweden were identified in the Swedish National Cervical Screening Registry. The odds ratio (OR) of HPV-16/18 infection was estimated comparing birth cohorts to the unvaccinated 1984-born using an age-period-cohort model. The impact of changing HPV prevalences on the number needed to screen (NNS) to detect and prevent 1 cervical cancer case was calculated.Results HPV vaccination coverage was 82%-83% among women born in 1999-2000. Before 2019, the HPV-16/18 prevalence was highest among the youngest women. During 2020-2023 the prevalence consistently decreased among the birth cohorts offered organized school-based vaccination. There was a 98% decline in HPV-16 prevalence (OR, 0.02 [95% confidence interval {CI}, .01-.04]) and a 99% decline in HPV-18 prevalence (OR, 0.01 [95% CI, .00-.04]) among the 2000-born compared to the 1984-born. The declining HPV-16/18 prevalences resulted in major increases in the NNS to detect and to prevent 1 case of cervical cancer.Conclusions The declines of HPV-16/18 were considerably larger than the vaccination coverage, suggesting herd immunity. The changing epidemiology of HPV types impacts screening needs, necessitating updated screening programs. We monitored the human papillomavirus (HPV) prevalence among the cervical screening population from 2014 to 2023. Among women eligible for school-based HPV vaccination, a 99% and 98% decline in HPV-16 and -18 infection, respectively, was observed. This indicates a strong overall protective effect.